Wave Life Sciences has reported promising preliminary results from its RNA editing drug for Alpha-1 antitrypsin deficiency, showing significant protein production without serious side effects. This milestone has boosted interest in RNA editing technologies, with several companies, including ProQr and Korro, advancing their own programs. As the field evolves, challenges remain in ensuring the efficacy and safety of these therapies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
